Cerebral blood flow and neurologic outcome when nimodipine is given after complete cerebral ischemia in the dog.
Ten minutes of complete cerebral ischemia was produced in 26 dogs by temporary ligation of the aorta and the venae cavae. Twenty dogs received nimodipine, a calcium entry blocker, 10 micrograms kg-1 i.v. 2 min after the ischemic period, followed by 1 microgram kg-1 min-1 for 2-3 h. Six dogs received only the solvent used for nimodipine. Fourteen dogs received nimodipine for 3 h and were subsequently evaluated neurologically up to 48 h postischemia. In the 12 other dogs, CBF and metabolism were followed for 2 h postischemia while either nimodipine or the solvent only was infused. The results were compared to previously published results for untreated dogs and dogs given nimodipine before the ischemic event. Nimodipine had the same effect on postischemic CBF whether started before or after the ischemic event, nearly doubling the flow when compared with untreated controls, whereas the solvent alone caused only a slight increase in CBF over control. By contrast, nimodipine initiated in the preischemic period significantly improved the neurologic outcome, but when initiated in the postischemic period the results were equivocal, such that the outcome was not significantly different from either the untreated group or the group in which nimodipine was initiated preischemia. Metabolic measurements did not give any indication of a specific effect of nimodipine, nor could the metabolic results be used as an indicator of neurologic outcome. The results are consistent with a beneficial effect of nimodipine following complete cerebral ischemia; however, evaluation of neurologic functional effects will require a more sensitive model.
D000818:Animals; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004285:Dogs; D004334:Drug Administration Schedule; D006454:Hemoglobins / Q000032:analysis; D009422:Nervous System Diseases / Q000209:etiology; D009539:Nicotinic Acids / Q000008:administration & dosage*; D009553:Nimodipine; D010100:Oxygen / Q000378:metabolism
D002121:Calcium Channel Blockers; D006454:Hemoglobins; D009539:Nicotinic Acids; D009553:Nimodipine; D010100:Oxygen